Dev Chatterjee

Transaction estimated at $13 bn per year

India has a demographic advantage and substantial growth and a political system that is relatively calm and consistent, Stephen Dainton, President of Barclays Bank PLC said

Shareholders of the firm to vote on Rashmi Saluja reappointment as director on Dec 31

Bankers anticipate deal-making to remain robust in 2025 with several marquee deals in the making

There is a new world order; India and Israel on the 'right side' of USA's equation: Nir Barkat

"We are looking at opportunities across all sectors and would like to import labour from India -both skilled and unskilled"

Large investors now assert their right to have a say in investee companies, underscore analysts

The GDP data for Q2 this year are a reflection of the vagaries of monsoons, as well as slower than expected consumption growth in urban areas

Jamshyd Godrej and Nyrika Holkar talked about the development of 1,000 acres of prime land in Mumbai, future investment plans, and the need for brand change

PM expresses grief, says his visionary leadership and unwavering commitment to excellence transformed the business landscape of India

Adani, others in $265 mn bribery case

The charges against Sagar stem from his role on the board of the Indian Energy Company, where he has served since October 2018

Noel Tata was named chairman of Tata Trusts, which holds 66% in Tata Sons, after Ratan Tata passed away last month. Soon after, Noel was inducted into Tata Sons board as a Trusts nominee director

Acquisitions to help build new airports, roads, Dharavi projects

This is mainly because of poor data for Q1FY25 due to election-related restrictions and uncertainties

US-based private equity major Blackstone may hold a majority stake in merged entity

Minutes from the October MPC show the RBI's optimism about private investments picking up

Profits remain flat; modest earnings growth is driven by BFSI cos, says Motilal report

Edtech unicorn hopes to turn the corner by FY25-end, says CEO

Torrent Group was actively pursuing the acquisition of Cipla and JB Chemicals and Pharmaceuticals but ultimately withdrew due to high valuations demanded by the sellers